SCHEMBL5367272

SCHEMBL5367272

Cc1cc2cc(C=O)c(=O)oc2cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 2/20 0.51
MAPT P10636 2/20 0.51
HPGD P15428 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HSD17B3 P37058 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
PTPN1 P18031 1/20 0.37
NQO1 P15559 2/20 0.37
GRIA1 P42261 1/20 0.34
GRIA2 P42262 1/20 0.34
GRIA3 P42263 1/20 0.34
GRIA4 P48058 1/20 0.34
PON1 P27169 1/20 0.34
MAOB P27338 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5377345 0.86 PTPN1 (0.50) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL15842309 0.84 HPGD (0.53) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL11584435 0.84 KDM4E (0.48) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL15842923 0.80 HSD17B3 (0.60) ALDH1A1HPGDHSD17B3CYP1A2NQO1
SCHEMBL5858393 0.79 MAOB (0.57) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL5288407 0.79 ALDH1A1 (0.60) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL11151090 0.75 CA12 (0.56) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL11618977 0.74 ALDH1A1 (0.44) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL26035476 0.73 HSD17B3 (0.44) MAPTHSD17B3NQO1PON1MAOB
SCHEMBL15842645 0.73 KDM4E (0.57) ALDH1A1KDM4EMAPTHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
US-6506763-B2 Useful in prevention and treatment of protein kinase related disorders such as cancer SUGEN, INC. 2003-01-14 US disclosed
US-6133305-A PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISORDERS SUCH AS CANCER SUGEN, INC. (US) 2000-10-17 US disclosed
WO-2000053313-A2 LANTHANIDE CATALYSTS FOR SYNTHESIS OF COMPOUNDS AND COMBINATORIAL LIBRARIES ARQULE, INC. (US) 2000-09-14 WO disclosed
US-4098799-A ANTIALLERGENS, HYPERACIDITY WARNER-LAMBERT COMPANY (US) 1978-07-04 US disclosed
US-4008252-A ANTIALLERGENS, ANTIHYPERACIDITY WARNER-LAMBERT COMPANY (US) 1977-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ALDH1A1 2044/4885KDM4E 2527/4885MAPT 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.